MedTrace Logo

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

NCT07804615 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-09-04

No results posted yet for this study

Summary

Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.

The main objectives of this clinical trial are to determine the following:

* Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease?
* Is VIM0423 well tolerated in individuals with Parkinsons's disease? and
* Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Conditions

  • PARKINSON DISEASE (Disorder)

Interventions

DRUG

VIM0423

VIM0423 is a combination drug product containing two active ingredients (VMA-1001 and VMA-1002)

DRUG

VIM0423 Placebo

Matching VIM0423 placebo product containing no active ingredient

Sponsors & Collaborators

  • Vima Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07804615 on ClinicalTrials.gov